The interplay between G9a and soluble WNT inhibitors was previously documented in neuroendocrine tumors, where DKK1 and DKK3 promoters are silenced by G9a-dependent H3K9 methylation [11,12]. The gene discussed is EHMT2; the disease is neuroendocrine neoplasm.